Intrinsic Value

The intrinsic value of AGFA Gevaert NV (AGE) under the Base Case is 0.16 EUR per share. Compared with the current market price of 0.315 EUR, the stock appears Overvalued by 49% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

AGE Intrinsic Value
€0.16
Overvaluation 49%
Intrinsic Value
Price €0.315
Alert me when AGE is below its intrinsic value
Today €0.128 · 59.4% below the current price

AGE is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alternatives to AGE

Fundamental Analysis

What AGFA Gevaert Does

Health Care

AGFA Gevaert makes imaging and printing products and software. Its business is split between healthcare and printing. In healthcare, it sells digital radiology systems, image management software, and related services that help hospitals and clinics capture, store, and review medical images. In printing, it sells offset printing plates, chemicals, and workflow systems that help commercial printers prepare and produce printed materials.

Headquarters
Belgium BE
Employees
4 211
IPO date
May 31, 1999
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · November 10, 2026

Agfa says its transformation is on track, while faster cloud migration weighs on near-term HealthCare IT profitability; management sees hydrogen recovery ahead and advances the DPS–EFI combination.

Open the earnings call
EPS
−€0.10
Expected
−€0.05
Surprise
−100.0%
Stock, day of the call
−6.9%
View Earnings Call

Past 12 months

Continue AGE Research

Decided on AGFA Gevaert? Get an email when AGE reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one AGE stock?

The intrinsic value for AGFA Gevaert NV (AGE) under the Base Case is 0.16 EUR.

Is AGE stock undervalued or overvalued?

Compared with the current market price of 0.315 EUR, the stock appears Overvalued by 49% .

How reliable are our estimates? See how past valuations played out
Back to Top